DENTSPLY SIRONA Inc. (XRAY) Presents Refined Strategy Roadmap At the Morgan Stanley 23rd Annual Global Healthcare Conference

With significant upside potential, DENTSPLY SIRONA Inc. (NASDAQ:XRAY) secures a spot on our list of the 15 Best Robotics Stocks to Buy Under $20.

At the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, 2025, CEO Dan Scavilla and CFO Matt Garza presented a refined strategy roadmap for DENTSPLY SIRONA Inc. (NASDAQ:XRAY).

In order to speed up decision-making, shift resources from support to R&D and sales, and increase U.S. market penetration before future product launches, the leadership revealed plans to enact structural reforms. DENTSPLY SIRONA Inc. (NASDAQ:XRAY) reiterated its aim of above 19% fiscal 2025 margins and $300–400 million annual cash flow, revisiting a $3 EPS goal for 2026, and forecasting a 2%–4% fall in organic revenue for 2025 and facing an annual tariff impact of $80 million.

Although DENTSPLY SIRONA Inc. (NASDAQ:XRAY)’s management acknowledged the difficulties in implementing ERP, they placed a strong emphasis on improving customer satisfaction, growing direct distribution channels, and taking into account bolt-on acquisitions in order to increase its total addressable market.

Through its four company segments—Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare—DENTSPLY SIRONA Inc. (NASDAQ:XRAY) creates, produces, and sells cloud-enabled dental tools, supplies, and healthcare solutions globally. It is one of the best robotic stocks.

While we acknowledge the potential of XRAY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 15 Stocks That Will Benefit From AI and 12 Best Quantum Computing Stocks to Buy According to Wall Street Analysts.

Disclosure: None.